Therapeutic compounds and compositions
AssigneeAgios Pharmaceuticals, Inc.
InventorsFrancesco G. Salituro, Jeffrey O. Saunders, Shunqi Yan
Life of this patent
Estimating the term…
Abstract
Compounds and compositions comprising compounds that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that modulate PKM2 in the treatment of cancer.
Claims57
A compound of formula II or a pharmaceutically acceptable salt thereof, wherein:
- W, X, Y and Z are each independently selected from CH or N;
- D and D1 are independently selected from a bond or NRb;
- L is a bond, —C(O)—, —(CRcRc)m—, —OC(O)—, —(CRcRc)m—OC(O)—, —(CRcRc)m—C(O)—, —NRbC(S)—, or —NRbC(O)— (wherein the point of the attachment to R1 is on the left-hand side);
- R1 is selected from alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl;
- each of which is substituted with 0-5 occurrences of Rd;
- each R3 is independently selected from halo, haloalkyl, alkyl, hydroxyl and —ORa or two adjacent R3 taken together with the carbon atoms to which they are attached form an optionally substituted heterocyclyl;
- each Ra is independently selected from alkyl, acyl, hydroxyalkyl and haloalkyl;
- each Rb is independently selected from hydrogen and alkyl;
- each Rc is independently selected from hydrogen, halo, alkyl, alkoxy and halo alkoxy or two Rc taken together with the carbon atoms to which they are attached form an optionally substituted cycloalkyl;
- each Rd is independently selected from halo, haloalkyl, haloalkoxy, alkyl, alkynyl, nitro, cyano, hydroxyl, —C(O)Ra, —OC(O)Ra, —C(O)ORa, —SRa, —NRaRb and —ORa, or two Rd taken together with the carbon atoms to which they are attached form an optionally substituted heterocyclyl;
- n is 0, 1, or 2;
- m is 1, 2 or 3;
- h is 1;
- and
- g is 1.
A pharmaceutical composition comprising a compound of formula II or a pharmaceutically acceptable salt thereof, wherein:
- W, X, Y and Z are each independently selected from CH or N;
- D and D1 are independently selected from a bond or NRb;
- L is a bond, —C(O)—, —(CRcRc)m—, —OC(O)—, —(CRcRc)m—OC(O)—, —(CRcRc)m—C(O)—, —NRbC(S)—, or —NRbC(O)— (wherein the point of the attachment to R1 is on the left-hand side);
- R1 is selected from alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl;
- each of which is substituted with 0-5 occurrences of Rd;
- each R3 is independently selected from halo, haloalkyl, alkyl, hydroxyl and —ORa, or two adjacent R3 taken together with the carbon atoms to which they are attached form an optionally substituted heterocyclyl;
- each Ra is independently selected from alkyl, acyl, hydroxyalkyl and haloalkyl;
- each Rb is independently selected from hydrogen and alkyl;
- each Rc is independently selected from hydrogen, halo, alkyl, alkoxy and halo alkoxy or two Rc taken together with the carbon atoms to which they are attached form an optionally substituted cycloalkyl;
- each Rd is independently selected from halo, haloalkyl, haloalkoxy, alkyl, alkynyl, nitro, cyano, hydroxyl, —C(O)Ra, —OC(O)Ra, —C(O)ORa, —SRa, —NRaRb and —ORa, or two Rd taken together with the carbon atoms to which they are attached form an optionally substituted heterocyclyl;
- n is 0, 1, or 2;
- m is 1, 2 or 3;
- h is 1;
- and
- g is 1.
A compound selected from one of the following:
A pharmaceutically acceptable salt of the compound:
A compound or a pharmaceutically acceptable salt thereof, wherein the compound is:
A pharmaceutical composition comprising a pharmaceutically acceptable salt of the compound:
A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt thereof, wherein the compound is:
Dependencies are inferred from the claim text.